Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Synairgen (SNG)

Price 4.77p on 26-11-2024 at 17:30:00
Change 0.12p 2.58%
Buy 5.04p
Sell 4.50p
Buy / Sell SNG Shares
Last Trade: Buy 10,000.00 at 4.8942p
Day's Volume: 79,892
Last Close: 4.77p
Open: 4.65p
ISIN: GB00B0381Z20
Day's Range 0.00p - 0.00p
52wk Range: 3.00p - 10.62p
Market Capitalisation: £9m
VWAP: 4.822282p
Shares in Issue: 203m

Recent Trades History Synairgen (SNG)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 10,000 4.8942p Ordinary
16:02:29 - 26-Nov-24
Sell* 227 4.5054p Ordinary
15:31:58 - 26-Nov-24
Buy* 20,432 4.8942p Ordinary
13:52:01 - 26-Nov-24
Buy* 10,134 4.8942p Ordinary
11:58:08 - 26-Nov-24
Sell* 94 4.55p Ordinary
10:34:38 - 26-Nov-24
Sell* 1,421 4.55p Ordinary
10:33:52 - 26-Nov-24
Sell* 2,662 4.55p Ordinary
10:25:52 - 26-Nov-24
Buy* 22,347 4.90p Ordinary
10:23:43 - 26-Nov-24
Sell* 11,976 4.55p Ordinary
09:41:17 - 26-Nov-24
Sell* 599 4.515p Ordinary
08:16:16 - 26-Nov-24

Share Price History for Synairgen

Time period:
to
Date Open High Low Close Volume

Share News for Synairgen

UK shareholder meetings calendar - next 7 days

3rd Oct 2024 15:46

Read More

EARNINGS: Hansard Global profit down; Flowtech cuts outlook

26th Sep 2024 19:33

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Synairgen slashes costs and focuses on small hospital trials

27th Jun 2024 12:04

Synairgen PLC - South Hampton, England-based drug discovery and development company focused on combatting respiratory disease - In 2023, pretax loss narrowed to GBP9.7 million from GBP20.1 million a year prior. No revenue generated. Research & Development expenditure down 56% to GBP6.5 million from GBP14.9 million. Other administrative expenses fell 30% to GBP3.8 million from GBP5.4 million. Cash and cash equivalents held at GBP10.5 million, down 34% from GBP15,9 million. Read More

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

7th May 2024 09:51

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday: Read More

IN BRIEF: Synairgen names Phytome's Joseph Colliver as CFO

11th Oct 2023 11:19

Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Appoints Joseph Colliver as chief financial officer with effect from November 6. Current CFO John Ward will step down from his role on November 3. Colliver has previously held CFO and senior commercial roles at Sativa Group Inc, and within the Kantar division of WPP PLC. He is currently CFO at Phytome Life Sciences Ltd, a pharmaceutical manufacturing firm focused on plant-based medicines. Read More

FTSE 100 Latest
Value8,258.61
Change-33.07

Login to your account

Forgot Password?

Not Registered